Trials / Not Yet Recruiting
Not Yet RecruitingNCT06929468
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Squamous Cell Carcinoma: A Cohort Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 55 (estimated)
- Sponsor
- Simon Jäger · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.
Conditions
- Ototoxic Hearing Loss
- Ototoxicity, Drug-Induced
- Cisplatin-induced Hearing Loss
- Cisplatin Ototoxicity
- Head and Neck Cancer
- Dizzyness
- Inner Ear Hearing Loss
- Vestibular Disease
- Squamous Cell Carcinoma of the Head and Neck
- Deafness
- Hearing Loss
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2025-04-16
- Last updated
- 2025-04-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06929468. Inclusion in this directory is not an endorsement.